Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says
Takeda’s incoming CEO took a firm stance against President Donald Trump’s “most favored nation” deals with drugmakers on Thursday, while Sanofi and Roche shared new details about their negotiations with the White House.
“In general ...
⚠️ 风险分析 中
摘要：武田制药反对美国MFN药品定价政策，多家药企与白宫谈判，显示跨境医药市场准入与定价风险。
影响：若美国推行强硬药品定价政策，可能影响包括中国药企在内的全球药企在美市场准入与利润，并可能引发其他市场效仿。
建议：药企需密切关注美国药品定价政策动向，评估对在美业务影响，并加强政府关系与合规管理。
「素履以往」
Not the sharpest mind, but the steadiest hand.
Not the sharpest mind, but the steadiest hand.